21:19 , Mar 22, 2019 |  BC Extra  |  Company News

Management tracks: Mirum, Novocure

Mirum said Mike Grey has stepped down as CEO but will remain executive chairman. Mirum Pharmaceuticals Inc. (San Francisco, Calif.) promoted President Chris Peetz to CEO. Peetz is also a director. Mirum launched in 2018...
23:23 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Endocrine/metabolic

INDICATION: Diabetes Mouse studies suggest agonizing GITR could help treat insulin resistance. In genetic and high-fat diet-induced mouse models of insulin resistance, a GITR agonist mAb increased glucose tolerance and insulin sensitivity and decreased fasting...
18:53 , Feb 7, 2019 |  BC Week In Review  |  Company News

Gilead reports $820M impairment on Kite anti-BCMA therapy

As Daniel O’Day prepares to step in as the company’s chairman and CEO, Gilead Sciences Inc. (NASDAQ:GILD) reported 4Q18 earnings that included an $820 million impairment charge for anti-BCMA therapy KITE-585, one of the compounds...
01:05 , Feb 5, 2019 |  BC Extra  |  Company News

Gilead reports $820M impairment on Kite anti-BCMA therapy

As Daniel O’Day prepares to step in as the company’s chairman and CEO, Gilead Sciences Inc. (NASDAQ:GILD) reported 4Q18 earnings that included an $820 million impairment charge for anti-BCMA therapy KITE-585, one of the compounds...
19:52 , Feb 1, 2019 |  BC Week In Review  |  Financial News

Agenus to sell blockchain tokens to fund PD-1 development

Agenus Inc. (NASDAQ:AGEN) said Jan. 29 that is seeking to raise up to $100 million via the sale of blockchain-powered tokens tied to clinical anti-PD-1 mAb AGEN2034. The company said the asset-backed digital security is...
19:21 , Jan 29, 2019 |  BC Extra  |  Financial News

Agenus to sell blockchain tokens to fund PD-1 development

Agenus Inc. (NASDAQ:AGEN) is seeking to raise up to $100 million via the sale of blockchain-powered tokens tied to clinical anti-PD-1 mAb AGEN2034. The company said the asset-backed digital security is the first of its...
19:25 , Dec 21, 2018 |  BC Week In Review  |  Company News

Gilead expands immuno-oncology pipeline with license from Agenus

Gilead Sciences Inc. (NASDAQ:GILD) received rights to a bispecific immuno-oncology molecule and options for two additional immuno-oncology candidates from Agenus Inc. (NASDAQ:AGEN). Gilead received exclusive, worldwide rights to AGEN1423, options to bispecific antibody AGEN1223 and...
00:06 , Dec 21, 2018 |  BC Extra  |  Company News

Gilead expands immuno-oncology pipeline with license from Agenus

Gilead Sciences Inc. (NASDAQ:GILD) received rights to a bispecific immuno-oncology molecule and options for two additional immuno-oncology candidates from Agenus Inc. (NASDAQ:AGEN). The deal, Gilead's second of the week, will also extend Agenus’ cash reserves....
00:30 , Nov 15, 2018 |  BC Extra  |  Company News

Management tracks: Ascletis, Agenus

Antiviral company Ascletis Pharma Inc. (HKSE:1672) hired Lindi Tan as CFO. She was a global healthcare analyst at SeaTown Holdings International. Ascletis was the first biotech to go public on the Hong Kong stock exchange's...
20:07 , May 18, 2018 |  BC Week In Review  |  Clinical News

Agenus shifts focus to cervical cancer from first-line NSCLC

Agenus Inc. (NASDAQ:AGEN) said in its 1Q18 earnings report that it shifted its developmental strategy to first seek approval of its checkpoint inhibitors as a second-line treatment for cervical cancer instead of as a first-line...